SWOG clinical trial number
CTSU/CALGB-40302
Endocrine Therapy with or without Inhibition of EGF and GER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer
Closed
Published
Abbreviated Title
ADVANCED: Fulvestrant +/- Lapatinib for Postmenopausal ER+ Patients
Activated
09/01/2006
Closed
07/14/2010
Participants
CTSU
Treatment
Fulvestrant
Lapatinib
Eligibility Criteria Expand/Collapse
The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.